The global Difficile Infections (Clostridium Difficile Associated Disease) Treatment market size is expected to surpass an impressive valuation of US$ 809 Million in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 6% from 2023 to 2033 to be valued at US$ 1,448.75 Million.
Clostridium difficile infection (CDI) is an illness caused by toxic substances generated by the "Clostridium difficile" spore-forming bacteria living in the big intestine. It belongs to the closely connected causal factors of antibiotic-related diarrhea, with signs ranging from mild, self-limiting diarrhea to chronic diarrhea, pseudomembranous colitis, and potentially fatal fulminant colitis. Antimicrobial drug consumption is predicted to drive expansion in the Clostridium difficile infection therapeutics market.
Report Attribute | Details |
---|---|
Expected Market Value (2022) | US$ 801 Million |
Market Value (2023) | US$ 809 Million |
Anticipated Forecast Value (2033) | US$ 1,448.75 Million |
Projected Growth Rate (2023 to 2033) | 6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Over the historical era, the difficile infection treatment market was influenced by the increasing incidence of clostridium-related illness and the growing worldwide aging population. Growing urbanization, an advanced healthcare system, and innovative technologies also enhanced market growth in the past years.
The aging global population is projected to propel the Clostridium Clostridium Difficile Infection Treatment market throughout the forecast period. Furthermore, modern lifestyles, advanced healthcare systems, and technological developments are predicted to propel market growth over the next several years. Also, the widespread use is expected to accelerate the expansion of the worldwide clostridium difficile infection treatment market.
Furthermore, the COVID-19 pandemic had a brief influence on the Clostridium Difficile Infection Therapeutics Market, as sales dropped during the virus's outbreak in 2020 due to massive losses in lifestyles and the global economy. Nevertheless, the industry regained following the development of vaccines and the withdrawal of COVID-19 restrictions.
Rising Utilization of Antibiotics to Accelerate Market Growth
Excessive drug development projects for creating and marketing new drugs are estimated to drive growth in the clostridium difficile infection treatment market by offering therapists a new therapeutic option. Moreover, the introduction of a new class of non-antibiotic medications and vaccines is expected to provide a plethora of possibilities for market participants while also growing the competitiveness for developing novel drugs as superior therapeutic approaches. As a result, higher drug programs for novel drugs to improve treatment and prevention are expected to propel the market's growth in the coming years.
Rising Utilization of Antibiotics accelerates Market Growth
Long-term antibiotic consumption is the most common cause of Clostridium difficile infection. Antibacterial drugs use changes the colorectal bacteria, enabling Clostridium difficile bacteria to thrive. Cephalosporins, clindamycin, and quinolone antibiotics seem to be more susceptible to causing Clostridium difficile infection (CDI).
The elevated utilization of these antibiotics is expanding the likelihood of Clostridium difficile infection, which is predicted to boost the requirement for its treatments. As a result, increased antibiotic usage is an important driver of expansion in the worldwide clostridium difficile infection treatment market.
Substantial Investments Required for Drug Development to restrict the market growth
Antibiotics are the only ongoing effective treatments for CDIs, and several pharmaceutical companies are attempting to develop non-antibiotic alternative solutions. The creation of a brand-new class of drugs will provide ample opportunities for industry participants to thrive, but it will also necessitate huge investments in novel therapy advancement and research. The significantly greater capital investments may act as a major impediment to industry growth.
Increased awareness of gastrointestinal infections drives the market growth
Because the infection is getting less prevalent, the market for clostridium difficile infection treatments is decreasing in European countries. The number of fatalities caused by healthcare-related CDI in Europe can be approximated at 3700 per year.
Because of the existence of mandatory monitoring, there has been improved compliance with isolation, personal hygiene, and cleanliness protocols, in addition to the tracking of antibiotic prescriptions. Because of greater awareness about gastrointestinal infection in the region, Europe is regarded as the second largest industry for clostridium difficile infection drugs.
An increase in suspected cases of difficile Infections (Clostridium Difficile Associated Disease) Treatment spurs the market
According to the Centers for Disease Control (CDC), clostridium difficile infects about half a million North Americans every year. Within one month of being diagnosed with C. difficile, nearly 29,000 patients died, with 15,000 of these death tolls being mainly ascribed to C. difficile infection. The Clostridium Difficile Infection industry will emerge significantly in the next few years as healthcare expenditure in this region rises, suspected cases of Clostridium difficile infection (CDI) increase and forthcoming treatments are anticipated to be launched.
With developments in molecular biology methods over the last two decades, there have been numerous advancements in comprehending the genetic variety, evolution, and pathogenicity of Clostridium difficile. In North America, recurring clinical and academic activities are anticipated to continue to resolve impediments in the coming decades. Furthermore, the United States had the highest proportion of Clostridium difficile infection, accounting for nearly 70% of all cases reported of Clostridium difficile infection worldwide.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The antibiotic segment is projected to expand quickly
Recently, standard antibiotics such as metronidazole, Vancomycin, and Fidaxomicin have been employed to cure Clostridium difficile infection (CDI). Presently, there are no alternatives to antibiotics for the treatment of Clostridium difficile infection, and surgical procedure remains the only option (in severe cases). As a result, the antibiotic segment is expected to grow rapidly over the forecast timeframe.
A rise in the number of hospitalized patients drives the market growth
The end-user market is dominated by the hospital segment. This, coupled with an increase in hospitalized patients and a greater focus on public health agencies, is anticipated to propel Hospital segment expansion during the forecast period.
Key players in the Difficile Infections (Clostridium Difficile Associated Disease) Treatment market are Roche AG, Thermo Fisher Scientific Inc., Merck & Co., Pfizer, Inc., Actelion Pharmaceuticals, Alere, Inc., Trinity Biotech, Summit Therapeutics, Baxter International Inc., Sanofi S.A., Novartis AG, and AstraZeneca Plc.
Report Attribute | Details |
---|---|
Market Value (2023) | US$ 809 Million |
Anticipated Forecast Value (2033) | US$ 1,448.75 Million |
Projected Growth Rate (2023 to 2033) | 6% CAGR |
Base Year for Estimation | 2022 |
Historical Data | 2018 to 2022 |
Forecast Period | 2023 to 2033 |
Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered | Treatment, Drug Type, End Users, Region |
Regions Covered | North America; Latin America; Western Europe; Eastern Europe; Asia Pacific; Middle East & Africa (MEA) |
Key Countries Profiled | The USA, Canada, Brazil, Mexico, BENELUX, Germany, The UK, France, Spain, Italy, Nordics, Poland, Russia, India, Malaysia, Singapore, Thailand, Australia, New Zealand, GCC, South Africa, Israel |
Key Companies Profiled | Merck & Co. Inc.; Baxter International Inc.; Sanofi S.A; Pfizer Inc.; Novartis AG; Astellas Pharma; Eli Lily & Company; AstraZeneca; Actelion Pharmaceuticals Ltd.; Mylan N.V |
Customization | Available Upon Request |
FMI projects the global Difficile Infections (Clostridium Difficile Associated Disease) Treatment market to expand at a 6% value CAGR by 2033.
The global Difficile Infections (Clostridium Difficile Associated Disease) Treatment market is estimated at a market value of US$ 809 Million.
The global Difficile Infections (Clostridium Difficile Associated Disease) Treatment market is expected to garner a market value of US$ 1,448.75 Million.
FMI has projected North America to be one of the key regions for the Difficile Infections (Clostridium Difficile Associated Disease) Treatment market.
Roche AG, Thermo Fisher Scientific Inc., Merck & Co., Pfizer, Inc., Actelion Pharmaceuticals, Alere, Inc., Trinity Biotech, Summit Therapeutics, Baxter International Inc., Sanofi S.A., Novartis AG, AstraZeneca Plc.
1. Executive Summary | Difficile Infections (Clostridium Difficile Associated Disease) Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Antimicrobial Therapy
5.3.2. Faecal Microbiota Transplantation
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033
6.3.1. Metronidazole
6.3.2. Vancomycin
6.3.3. Fidaxomicin
6.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033
7.3.1. Hospital
7.3.2. Pharmacies
7.3.3. ASCs
7.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. Asia-Pacific
8.3.6. Middle East & Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. The US
9.2.1.2. Canada
9.2.2. By Treatment
9.2.3. By Drug Type
9.2.4. By End Users
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By Drug Type
9.3.4. By End Users
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Treatment
10.2.3. By Drug Type
10.2.4. By End Users
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By Drug Type
10.3.4. By End Users
10.4. Key Takeaways
11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Benelux
11.2.1.2. France
11.2.1.3. Germany
11.2.1.4. Italy
11.2.1.5. Nordic
11.2.1.6. Spain
11.2.1.7. The UK
11.2.1.8. Rest of Western Europe
11.2.2. By Treatment
11.2.3. By Drug Type
11.2.4. By End Users
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By Drug Type
11.3.4. By End Users
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Rest of Eastern Europe
12.2.2. By Treatment
12.2.3. By Drug Type
12.2.4. By End Users
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By Drug Type
12.3.4. By End Users
12.4. Key Takeaways
13. APAC Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Australia
13.2.1.6. New Zealand
13.2.1.7. Rest of APAC
13.2.2. By Treatment
13.2.3. By Drug Type
13.2.4. By End Users
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment
13.3.3. By Drug Type
13.3.4. By End Users
13.4. Key Takeaways
14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Treatment
14.2.3. By Drug Type
14.2.4. By End Users
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Treatment
14.3.3. By Drug Type
14.3.4. By End Users
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. The US
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Treatment
15.1.2.2. By Drug Type
15.1.2.3. By End Users
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Treatment
15.2.2.2. By Drug Type
15.2.2.3. By End Users
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Treatment
15.3.2.2. By Drug Type
15.3.2.3. By End Users
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Treatment
15.4.2.2. By Drug Type
15.4.2.3. By End Users
15.5. Benelux
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Treatment
15.5.2.2. By Drug Type
15.5.2.3. By End Users
15.6. France
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Treatment
15.6.2.2. By Drug Type
15.6.2.3. By End Users
15.7. Germany
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Treatment
15.7.2.2. By Drug Type
15.7.2.3. By End Users
15.8. Italy
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Treatment
15.8.2.2. By Drug Type
15.8.2.3. By End Users
15.9. Nordic
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Treatment
15.9.2.2. By Drug Type
15.9.2.3. By End Users
15.10. Spain
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Treatment
15.10.2.2. By Drug Type
15.10.2.3. By End Users
15.11. The UK
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Treatment
15.11.2.2. By Drug Type
15.11.2.3. By End Users
15.12. Poland
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Treatment
15.12.2.2. By Drug Type
15.12.2.3. By End Users
15.13. Russia
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Treatment
15.13.2.2. By Drug Type
15.13.2.3. By End Users
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Treatment
15.14.2.2. By Drug Type
15.14.2.3. By End Users
15.15. Malaysia
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Treatment
15.15.2.2. By Drug Type
15.15.2.3. By End Users
15.16. Singapore
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Treatment
15.16.2.2. By Drug Type
15.16.2.3. By End Users
15.17. Thailand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Treatment
15.17.2.2. By Drug Type
15.17.2.3. By End Users
15.18. Australia
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Treatment
15.18.2.2. By Drug Type
15.18.2.3. By End Users
15.19. New Zealand
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Treatment
15.19.2.2. By Drug Type
15.19.2.3. By End Users
15.20. GCC Countries
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Treatment
15.20.2.2. By Drug Type
15.20.2.3. By End Users
15.21. South Africa
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Treatment
15.21.2.2. By Drug Type
15.21.2.3. By End Users
15.22. Israel
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Treatment
15.22.2.2. By Drug Type
15.22.2.3. By End Users
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Treatment
16.3.3. By Drug Type
16.3.4. By End Users
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Merck & Co., Inc.
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Baxter International Inc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Sanofi S.A.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Pfizer Inc.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Novartis AG
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Astellas Pharma
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Eli Lily & Company
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. AstraZeneca
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Actelion Pharmaceuticals Ltd
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Mylan N.V.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports